1
|
Wu H, Li S, Hu X, Qin W, Wang Y, Sun T, Wu Z, Wang X, Lu S, Xu D, Li Y, Guan S, Zhao H, Yao W, Liu M, Wei M. Associations of mRNA expression of DNA repair genes and genetic polymorphisms with cancer risk: a bioinformatics analysis and meta-analysis. J Cancer 2019; 10:3593-3607. [PMID: 31333776 PMCID: PMC6636297 DOI: 10.7150/jca.30975] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Accepted: 05/16/2019] [Indexed: 12/21/2022] Open
Abstract
A systematical bioinformatics and meta-analysis were carried out to establish our understanding of possible relationships between DNA repair genes and the development of cancer. The bioinformatics analysis confirmed that lower XPA and XPC levels and higher XPD, XPF, and WRN levels were observed in 19 types of cancer, and subsequently results indicated that elevated XPA and XPC had a better impact on overall survival, however, higher XPD, XPF, and WRN showed worse influence on cancer prognosis. The meta-analysis included 58 eligible studies demonstrated that harboring XPA rs10817938, XPD rs238406 increased overall cancer risk, however, XPA rs2808668 SNP in overall cancer analysis and XPF rs3136038 in the digestive system remarkably reduced the cancer risk. Moreover, no correlation was investigated for XPC rs1870134, WRN rs1346044 and rs1801195. These suggest that the DNA repair gene was associated with carcinogenesis, and contribute to the prognosis, and the critical SNPs further involved in affecting cancer risk.
Collapse
Affiliation(s)
- Huizhe Wu
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Shanqiong Li
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Xiaoyun Hu
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Wenyan Qin
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Yilin Wang
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Tong Sun
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China.,Department of Anorectal Surgery, First Hospital of China Medical University, Shenyang, 110001, P. R. China.,Department of Breast Surgery, First Hospital of China Medical University, Shenyang, 110001, P. R. China
| | - Zhikun Wu
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Xiufang Wang
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Senxu Lu
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Dongping Xu
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Yalun Li
- Department of Anorectal Surgery, First Hospital of China Medical University, Shenyang, 110001, P. R. China
| | - Shu Guan
- Department of Breast Surgery, First Hospital of China Medical University, Shenyang, 110001, P. R. China
| | - Haishan Zhao
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Weifan Yao
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Mingyan Liu
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| | - Minjie Wei
- Department of Pharmacology, School of Pharmacy, Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, 110122, P. R. China
| |
Collapse
|
2
|
Tong Y, Xiang Y, Li B, Bao S, Zhou Y, Yuan W, Ling Y, Hao D, Zhu H, Sun Z. Association of ERCC2 Gene Polymorphisms with Susceptibility to Diffuse Large B-Cell Lymphoma. Med Sci Monit 2018; 24:7015-7022. [PMID: 30279407 PMCID: PMC6179170 DOI: 10.12659/msm.908813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The objective of this study was to detect the association between ERCC excision repair 2, TFIIH core complex helicase subunit (ERCC2) gene polymorphisms and diffuse large B-cell lymphoma (DLBCL) susceptibility. MATERIAL AND METHODS This study used a case-control design. ERCC2 gene rs1799793 (Asp312Asn) and rs13181 (Lys751Gln) polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) both in DLBCL patients and healthy controls. The association between ERCC2 gene polymorphisms and DLBCL risk was assessed by χ² test. Odds ratios (ORs) with corresponding 95% confidence intervals (95% CIs) were used to address the association strength. Subgroup analyses were also performed to investigate the genetic effects of ERCC2 polymorphisms on clinical characteristics of DLBCL patients. RESULTS A significant association was discovered between the rs1799793 A allele and increased DLBCL risk (P=0.031, OR=1.928, 95% CI=1.052-3.534). The C allele of rs13181 was obviously associated with elevated DLBCL susceptibility (P=0.047, OR=1.820, 95% CI=1.002-3.305). The subgroup analysis demonstrated that rs1799793 and rs13181 polymorphisms had no relationship with serum lactate dehydrogenase level, nidus number, B-symptoms, Ann Arbor stages, or immunological types in DLBCL cases (P>0.05 for all). CONCLUSIONS Minor allele carriers of ERCC2 gene rs1799793 (Asp312Asn) and rs13181 (Lys751Gln) polymorphisms had higher susceptibility to DLBCL.
Collapse
Affiliation(s)
- Yong Tong
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Yinzhou Xiang
- Department of Otolaryngology, China Three Gorges University People's Hospital, Yichang, Hubei, China (mainland)
| | - Bao Li
- Department of Hematopathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China (mainland)
| | - Shijie Bao
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Ying Zhou
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Wen Yuan
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Yu Ling
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Dan Hao
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Huamin Zhu
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| | - Zhiqiang Sun
- Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China (mainland)
| |
Collapse
|
3
|
Xiao F, Pu J, Wen Q, Huang Q, Zhang Q, Huang B, Huang S, Lan A, Zhang Y, Li J, Zhao D, Shen J, Wu H, He Y, Li H, Yang X. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer. Oncotarget 2018; 8:48488-48506. [PMID: 28489582 PMCID: PMC5564664 DOI: 10.18632/oncotarget.17290] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Accepted: 04/04/2017] [Indexed: 01/18/2023] Open
Abstract
Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. The relationship between genetic polymorphisms and the risk of cancers has been widely researched. Excision repair cross-complementing group 2 (ERCC2) gene plays important roles in the nucleotide excision repair pathway. There is contrasting evidence on the association between the ERCC2 Asp312Asn polymorphism and the risk of cancer. We conducted a comprehensive meta-analysis in order to assess the correlation between these factors. We searched the PubMed, EMBASE, Science Direct, Web of Science, and CNKI databases for studies published from January 1, 2005 to January 1, 2016. Finally, 86 articles with 38,848 cases and 48,928 controls were included in the analysis. The overall analysis suggested a significant association between the ERCC2 Asp312Asn polymorphism and cancer risk. Furthermore, control source, ethnicity, genotyping method, and cancer type were used for subgroup analysis. The result of a trial sequential analysis indicated that the cumulative evidence is adequate; hence, further trials were unnecessary in the overall analysis for homozygote comparison. In summary, our results suggested that ERCC2 Asp312Asn polymorphism is associated with increased cancer risk. A significantly increased cancer risk was observed in Asian populations, but not in Caucasian populations. Furthermore, the ERCC2 Asp312Asn polymorphism is associated with bladder, esophageal, and gastric cancers, but not with breast, head and neck, lung, prostate, and skin cancers, and non-Hodgkin lymphoma. Further multi-center, well-designed studies are required to validate our results.
Collapse
Affiliation(s)
- Feifan Xiao
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China.,First Clinical Academy, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Jian Pu
- Liver and Gall Surgical Department, The Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, P.R. China
| | - Qiongxian Wen
- School of Nursing, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, P.R. China
| | - Qin Huang
- Guangxi Key Laboratory of Chemistry and Engineering of Forest Products, Guangxi University for Nationalities, Nanning, Guangxi, P.R. China
| | - Qinle Zhang
- Genetic and Metabolic Central Laboratory, The Maternal and Children Health Hospital of Guangxi, Nanning, Guangxi, P.R. China
| | - Birong Huang
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China.,First Clinical Academy, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Shanshan Huang
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China.,First Clinical Academy, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Aihua Lan
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China.,First Clinical Academy, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Yuening Zhang
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Jiatong Li
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Dong Zhao
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Jing Shen
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Huayu Wu
- Department of Cell Biology and Genetics, School of Premedical Sciences, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Yan He
- Geriatrics Cardiology Division, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Hongtao Li
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
| | - Xiaoli Yang
- Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
| |
Collapse
|
4
|
ElMahgoub IR, Gouda HM, Samra MA, Shaheen IA, ElMaraashly AH. Polymorphisms of xeroderma pigmentosum genes (XPC, XPD, and XPG) and susceptibility to acute leukemia among a sample of Egyptian patients. J Hematop 2017. [DOI: 10.1007/s12308-017-0290-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
|
5
|
Zhou JY, He LW, Liu J, Yu HL, Wei M, Ma WL, Shi R. Comprehensive Assessment of Associations between ERCC2 Lys751Gln/Asp312Asn Polymorphisms and Risk of Non-Hodgkin Lymphoma. Asian Pac J Cancer Prev 2014; 15:9347-53. [DOI: 10.7314/apjcp.2014.15.21.9347] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|